识别重度饮酒者肝病进展高风险的模型
该研究基于2334例重度饮酒者(每日饮酒≥50g)且肝功能持续异常的患者数据,开发并验证了一个整合饮酒史、肝病分期、人口学特征的马尔可夫模型,用于预测肝病进展(肝细胞癌和/或肝功能失代偿)风险。模型显示5年加权风险>5%视为高风险,不同基线肝组织学阶段风险差异显著。
要点
- 基于饮酒量、饮酒起始年龄、性别和BMI的马尔可夫模型可预测肝病进展风险。
- 基线F3-F4纤维化者5年加权并发症风险高(男24.5%,女30.1%)。
- 5年加权风险>5%定义为肝病进展高风险,可用于调整诊疗路径。
核心结论
- 开发了一个整合饮酒水平与持续时间的马尔可夫模型,可识别肝病进展高风险患者,可能用于调整患者照护路径。
研究设计与样本
- 根据是否有肝活检,患者被分配到开发队列(n=1599,75%男性)或验证队列(n=735,75%男性)。
- 开发队列用METAVIR评分评估疾病严重程度,验证队列仅评估是否存在肝脏并发症。
- 模型拟合开发队列并在验证队列中评估,预测任何患者特征的疾病进展(基线评估)。
主要发现
- 对于40岁、25岁开始饮酒、每日饮酒150g、BMI 22 kg/m2的男性和女性,根据基线疾病严重程度给出了模型结果。
- 基线F0-F2纤维化的男性,基线正常肝、脂肪变、脂肪性肝炎的概率分别为31.8%、61.5%、6.7%;5年加权肝并发症风险为1.9%,范围从基线正常肝的0.2%到基线脂肪性肝炎的10.3%。
- 基线F0-F2纤维化的女性,基线正常肝、脂肪变、脂肪性肝炎的概率分别为25.1%、66.5%、8.4%;5年加权肝并发症风险为3.2%,范围从基线正常肝的0.5%到基线脂肪性肝炎的14.7%。
- 基线F3-F4纤维化的男性5年加权并发症风险为24.5%(范围20.2%-34.5%),女性为30.1%(范围24.7%-41.0%)。
关键数值与推荐
- 5年加权肝并发症风险大于5%的患者被认为是疾病进展高风险。
临床怎么用
- 该模型可用于识别重度饮酒者中肝病进展高风险个体,从而调整患者照护路径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Alcohol-related liver disease (ALD) causes chronic liver disease. We investigated how information on patients' drinking history and amount, stage of liver disease, and demographic feature can be used to determine risk of disease progression. METHODS: We collected data from 2334 heavy drinkers (50 g/day or more) with persistently abnormal results from liver tests who had been admitted to a hepato-gastroenterology unit in France from January 1982 through December 1997; patients with a recorded duration of alcohol abuse were assigned to the development cohort (n=1599; 75% men) or the validation cohort (n=735; 75% men), based on presence of a liver biopsy. We collected data from both cohorts on patient history and disease stage at the time of hospitalization. For the development cohort, severity of the disease was scored by the METAVIR (due to the availability of liver histology reports); in the validation cohort only the presence of liver complications was assessed. We developed a model of ALD progression and occurrence of liver complications (hepatocellular carcinoma and/or liver decompensation) in association with exposure to alcohol, age at the onset of heavy drinking, amount of alcohol intake, sex and body mass index. The model was fitted to the development cohort and then evaluated in the validation cohort. We then tested the ability of the model to predict disease progression for any patient profile (baseline evaluation). Patients with a 5-y weighted risk of liver complications greater than 5% were considered at high risk for disease progression. RESULTS: Model results are given for the following patient profiles: men and women, 40 y old, who started drinking at an age of 25 y, drank 150 g/day, and had a body mass index of 22 kg/m2 according to the disease severity at baseline evaluation. For men with baseline F0-F2 fibrosis, the model estimated the probabilities of normal liver, steatosis, or steatohepatitis at baseline to be 31.8%, 61.5% and 6.7%, respectively. The 5-y weighted risk of liver complications was 1.9%, ranging from 0.2% for men with normal liver at baseline evaluation to 10.3% for patients with steatohepatitis at baseline. For women with baseline F0-F2 fibrosis, probabilities of normal liver, steatosis, or steatohepatitis at baseline were 25.1%, 66.5% and 8.4%, respectively; the 5-y weighted risk of liver complications was 3.2%, ranging from 0.5% for women with normal liver at baseline to 14.7% for patients with steatohepatitis at baseline. Based on the model, men with F3-F4 fibrosis at baseline have a 24.5% 5-y weighted risk of complications (ranging from 20.2% to 34.5%) and women have a 30.1% 5-y weighted risk of complications (ranging from 24.7% to 41.0%). CONCLUSIONS: We developed a Markov model that integrates data on level and duration of alcohol use to identify patients at high risk of liver disease progression. This model might be used to adapt patient care pathways.
引用
- Delacôte C, Bauvin P, Louvet A, et al. A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. Clin Gastroenterol Hepatol. 2020. PMID: 31931181. doi:10.1016/j.cgh.2019.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。